Parmax Pharma

45.40
-0.10
(-0.22%)
Market Cap
17.00 Cr
EPS
-34.73
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
55.02
52 Week Low
25.03
PB Ratio
-21.04
Debt to Equity
1.91
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,699.80
#1 3,99,825.20
34.84
#1 49,887.20
12.06
#1 9,648
-18.99
45.69
6,631.50
1,76,164.90
80.39
8,184.00
0.89
1,600
23.05
64.51
1,476.90
1,18,598.30
22.50
26,520.70
14.17
4,155
30.28
46.70
3,161.10
1,07,148.40
55.51
10,785.70
11.59
1,656
10.91
42.78
1,248.20
1,03,689.40
#1 18.35
28,905.40
12.36
5,578
21.14
66.73
2,461.80
1,02,476.30
51.58
10,615.60
19.57
1,942
-10.91
48.11
924.75
93,137.00
19.93
19,831.50
13.82
3,831
-0.19
61.49
1,970.10
88,642.00
27.02
20,141.50
#1 19.94
1,936
#1 112.49
44.46
1,172.90
66,664.40
19.30
29,559.20
17.55
3,169
-0.50
47.14
30,350.00
64,002.90
45.31
6,097.20
10.80
1,201
27.83
49.13
Forecast
Actual
Growth Rate
Revenue Growth
-28.39 %
Net Income Growth
5,700.00 %
Cash Flow Change
-157.58 %
ROE
4,57,560.67 %
ROCE
-2,177.78 %
EBITDA Margin (Avg.)
-301.82 %

Yearly Financial Results

Annual Financials
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
0
0
12
12
21
26
18
16
11
28
Expenses
0
0
11
11
19
23
16
13
14
28
EBITDA
0
0
1
1
2
4
3
2
-3
0
Operating Profit %
0 %
0 %
9 %
9 %
8 %
13 %
14 %
15 %
-31 %
-2 %
Depreciation
0
0
1
1
1
2
2
2
2
2
Interest
0
0
0
0
0
0
0
0
1
1
Profit Before Tax
0
0
0
0
1
1
0
0
-6
-2
Tax
0
0
0
0
0
1
0
0
0
0
Net Profit
0
0
0
0
0
1
0
-0
-6
-2
EPS in ₹
-0.01
-0.02
0.00
0.21
1.15
2.02
0.38
-0.28
-34.73
-5.50

Balance Sheet

Balance Sheet
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
5
8
17
20
21
23
18
18
15
Fixed Assets
3
3
6
5
10
11
10
10
9
Current Assets
2
4
9
9
9
10
7
8
6
Capital Work in Progress
0
0
0
3
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
Other Assets
3
5
11
11
11
12
8
8
6
Total Liabilities
5
8
17
20
21
23
18
18
15
Current Liabilities
0
2
10
10
11
11
7
7
9
Non Current Liabilities
1
1
2
5
5
6
5
5
6
Total Equity
5
5
5
5
5
6
6
6
0
Reserve & Surplus
0
0
0
0
1
1
2
1
-4
Share Capital
5
5
5
5
5
5
5
5
5

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-0
0
-0
1
1
0
1
-2
-1
-0
Investing Activities
0
0
-0
-4
-3
-2
-3
-2
-1
-2
Operating Activities
-0
0
-1
4
1
3
4
1
0
-0
Financing Activities
0
0
1
1
3
-0
0
-1
0
1

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.80 %
30.83 %
30.80 %
30.80 %
30.80 %
30.80 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
68.09 %
68.03 %
67.93 %
67.98 %
68.01 %
68.00 %
65.37 %
65.36 %
65.38 %
65.42 %
65.43 %
65.43 %
65.34 %
65.78 %
62.90 %
63.12 %
63.10 %
Others
1.10 %
1.17 %
1.27 %
1.22 %
1.19 %
1.20 %
3.83 %
3.84 %
3.81 %
3.78 %
3.76 %
3.77 %
3.83 %
3.42 %
6.29 %
6.08 %
6.10 %
No of Share Holders
0
928
1,188
1,344
1,526
1,551
1,590
1,01,650
1,997
1,978
1,973
2,002
2,099
2,185
2,246
2,334
2,356

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 45.90 45.50
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 43.50 41.00
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 46.70 48.91
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 44.20 49.08

Announcements

Board Meeting Intimation for Meeting Of The Board Of Directors Will Be Held On Friday 30Th May 2025 At 4.00 PM Inter Alia To Consider Approve The Audited Financial Results Of The Quarter And Financial Year Ended On 31St March 20257 days ago
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2025
Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) 2015 For The Year Ended On 31St March 2025.Apr 21, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 12, 2025
Closure of Trading WindowMar 24, 2025
Integrated Filing (Financial)Feb 14, 2025
Financial Results For The Quarter Ended On 31St December 2024Feb 14, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 14, 2025
Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 To Consider Approve TheFeb 06, 2025
Closure of Trading WindowDec 28, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 13, 2024
Reason For Delay In Filing Financial Statements For The Quarter Ended On 30Th September, 2024.Dec 02, 2024
Financial Results For The Quarter And Half Year Ended On 30Th September, 2024Nov 15, 2024
Board Meeting Outcome for Outcome Of Board Meeting Of PARMAX PHARMA LIMITED Held O 14Th November, 2024Nov 15, 2024
Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 SEBI (LODR) Regulations, 2015 To Consider, Approve The Un-Audited Financial Results For The Quarter Ended 30Th September, 2024Nov 06, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 10, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 02, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 27, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 07, 2024
Reg. 34 (1) Annual Report.Sep 06, 2024
Intimation For Book Closure Under Regulation 42 Of SEBI (LODR) Regulations, 2015Sep 06, 2024
NOTICE IS HEREBY GIVEN THAT THE 30TH ANNUAL GENERAL MEETING OF THE MEMBERS OF PARMAX PHARMA LIMITED WILLBE HELD ON MONDAY, 30TH DAY OF SEPTEMBER, 2024, AT 3.00 P.M. AT THE REGISTERED OFFICE OF THE COMPANY SITUATEDAT PLOT NO. 20, SURVEY NO. 52, RAJKOT-GONDAL NATIONAL HIGHWAY NO. 27, HADAMTALA, TAL. KOTDA SANGANI, DIST.RAJKOT - 360 311 GUJARAT.Sep 06, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2024
Financial Results For Quarter Ended On 30/06/2024Aug 14, 2024
Board Meeting Outcome for OUTCOME OF BOARD MEETINGAug 14, 2024
Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Regulation 29 Read With Regulation 33 Of SEBI (LODR) Regulations, 2015.Aug 06, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 06, 2024
Closure of Trading WindowJun 28, 2024
Board Meeting Outcome for Revised OutcomeJun 08, 2024
Certificate For Non Applicability Of The Provision Of Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter And Year Ended On 31St March, 2024.May 31, 2024
The Board Of Directors Of The Company Has, At Its Meeting Held Today, Inter Alia, Considered And Approved The Audited Financial Results Of The Company For The Quarter And Year Ended On March 31, 2024May 30, 2024
Board Meeting Outcome for Board Of Directors Of The Company Has, Onsidered And Approved The Audited Financial Results Of The Company For The Quarter And Year Ended On March 31, 2024May 30, 2024
Update on board meetingMay 27, 2024
Board Meeting Intimation for To Approve The Audited Financial Statements For The Quarter And Year Ended On 31.03.2024.May 20, 2024
Appointment of Company Secretary and Compliance OfficerMay 02, 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2024
CERTIFICATE FROM PRACTICING COMPANY SECRETARY UNDER SEBI REGULATION 40(9)Apr 29, 2024
Compliance Certificate Pursuant To Regulation 7(3)Apr 12, 2024
Compliance Certificate Pursuant To Regulation 7(3)Apr 12, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Apr 07, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateApr 02, 2024
Closure of Trading WindowMar 28, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateFeb 20, 2024
Board Meeting Outcome for Financial Results For Quarter And Nine Months Ended 31.12.2023Feb 14, 2024
Financial Results For Quarter And Nine Months Ended 31.12.2023Feb 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateFeb 07, 2024
Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results For Quarter Ended 31St Deccember, 2023.Feb 07, 2024
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJan 31, 2024

Technical Indicators

RSI(14)
Neutral
51.05
ATR(14)
Less Volatile
3.41
STOCH(9,6)
Neutral
42.65
STOCH RSI(14)
Neutral
40.10
MACD(12,26)
Bearish
-0.16
ADX(14)
Weak Trend
9.39
UO(9)
Bearish
46.27
ROC(12)
Uptrend But Slowing Down
2.13
WillR(14)
Neutral
-64.93